Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Exercise boosts heart health in endometrial cancer survivors

NCT ID NCT06534008

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a 12-week program of aerobic and strength exercises could improve heart health and fitness in women who finished treatment for endometrial cancer. Thirty-three survivors in remission took part. They received exercise equipment and a Fitbit, and had heart and fitness tests before and after the program.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

33 people

The number who actually took part.

Started

Jul 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Willing and able to provide written informed consent * Willing to comply with study procedures and available for the duration of the study * Fluent in spoken and written English * Women 18 years of age or older * Documented diagnosis of Type I, stage I-IIIc endometrial cancer within the past 5 years * Completion of current cytotoxic treatment for endometrial cancer * Technology access (phone call access, broadband internet, Wi-Fi) for tele coaching * Comfort and willingness to use technology (videoconferencing) throughout the study for coaching * Pass the Physical Activity Readiness Questionnaire (PAR-Q) * Medical clearances given by their primary provider / oncologist (if indicated by the PAR-Q) Exclusion Criteria * Absolute contraindications to exercise (i.e., acute myocardial infarction, severe orthopedic or musculoskeletal limitations) * History of previous myocardial infarction, ischemia, or hemorrhagic stroke * Medically documented history of heart disease including heart valve disease, coronary artery disease, heart failure, peripheral artery disease, aortic disease, pericardial disease, cerebrovascular disease, or deep vein thrombosis * Medical documentation of treatment-resistant hypertension OR taking ≥2 medications to treat hypertension * Medically documented history of cardiovascular disease including (but not limited to): bypass surgery, stent procedures, bypass grafts, or coronary angioplasty * Medically documented or self-reported type 1 diabetes (insulin-dependents) * Prescriptions for or use of semaglutide (GLP-1 agonists) including name brands: Ozempic, Wegovy or Mounjaro * Current or recent (within last 3 months) use of hormone replacement therapy (HRT) * Evidence of recurrent or metastatic disease * Currently performing resistance training ≥2 days per week * Currently exceeding 150 minutes of at least moderate intensity exercise per week * Report of chest pain, shortness of breath, fainting, or angina pectoris * Self-reported history of falling, fall risk * Have physical disability that would limit range of motion through exercises such as sitting, standing and inability to walk one block * Plans to move from the area * Enrolled in another clinical trial or has used of any investigational drugs, biologics, or devices within 30 days prior to study enrollment * Self-reported tobacco use in last 7 days, current smoking, current tobacco use including e-cigarettes and vaping devices * Not suitable for study participation due to other reasons at the discretion of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Iowa

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.